Sun Pharma unit to invest Rs 3,000 cr on new plant in Madhya Pradesh

Sun Pharmaceutical Industries' subsidiary, Sun Pharma Laboratories Ltd, has approved a Rs 3,000 crore investment for a new greenfield formulations manufacturing facility in Madhya Pradesh. This significant expansion by the Mumbai-based drug major aims to bolster its production capabilities. The announcement comes as Sun Pharma's shares saw a slight increase on Wednesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F76BokX
via IFTTT

Read More

India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make semaglutide

The order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape competitive dynamics in a market valued at around Rs 850 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZcG9JDB
via IFTTT

Read More

Novo Nordisk India partners with Healthify to launch AI-enabled patient support programme

Novo Nordisk India and Healthify have launched a new programme. It offers AI-assisted lifestyle guidance for people with obesity. This partnership aims to improve patient experience and treatment results. An AI assistant will help users track nutrition throughout their treatment journey.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NrLORbi
via IFTTT

Read More

HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26

The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglutide. This decision comes amidst a patent infringement case filed by Novo Nordisk. Dr Reddy's is restricted from selling the drug within India until March 2026. The court acknowledged a valid challenge to Novo Nordisk's patent for semaglutide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/upk0RgU
via IFTTT

Read More

Jubilant Pharmova names Daniel J O'Connor as CEO of proprietary drugs biz

Jubilant Pharmova has appointed Daniel J O'Connor as the CEO of its novel drugs business. O'Connor brings over 30 years of leadership experience in biotechnology and oncology. His expertise includes creating value around differentiated, IP-rich platforms. Previously, he was CEO of Ambrx Biopharma, where his leadership led to a significant increase in company valuation and its successful acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9ITnu4N
via IFTTT

Read More

Cough syrup row puts regulators on overdrive to test pharma products

Indian drug companies are significantly increasing product testing. This surge follows strict government rules and joint inspections by regulators. The focus is on ensuring quality after recent contamination issues. Testing volumes have jumped dramatically. Companies are investing in specialized equipment to detect toxic substances. This heightened vigilance aims to safeguard public health and maintain the integrity of India's pharmaceutical industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p2w1POC
via IFTTT

Read More

Wockhardt gets NDA status for novel antibiotic Zaynich

Wockhardt, an emerging powerhouse in the Indian pharmaceutical arena, has just scored a game-changing triumph! The US health regulator has given the green light to its New Drug Application for Zaynich, a cutting-edge antibiotic. This pivotal moment signifies the first occurrence of an Indian firm securing FDA acceptance for a New Chemical Entity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYnqwyE
via IFTTT

Read More